Ensysce Biosciences Inc (NASDAQ:ENSC)’s traded shares stood at 18.42 million during the last session, with the company’s beta value hitting 0.87. At the close of trading, the stock’s price was $0.40, to imply a decrease of -25.57% or -$0.14 in intraday trading. The ENSC share’s 52-week high remains $2.06, putting it -415.0% down since that peak but still an impressive 65.0% since price per share fell to its 52-week low of $0.14. The company has a valuation of $5.98M, with an average of 77.74 million shares in intraday trading volume over the past 10 days and average of 13.46 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Ensysce Biosciences Inc (ENSC), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ENSC a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ensysce Biosciences Inc (NASDAQ:ENSC) trade information
After registering a -25.57% downside in the last session, Ensysce Biosciences Inc (ENSC) has traded red over the past five days. The 5-day price performance for the stock is 132.18%, and 34.18% over 30 days. With these gigs, the year-to-date price performance is -62.15%. Short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) saw shorts transact 0.18 million shares and set a 0.54 days time to cover.
Ensysce Biosciences Inc (ENSC) estimates and forecasts
Looking at statistics comparing Ensysce Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Ensysce Biosciences Inc (ENSC) shares are -28.18% down over the last 6 months, with its year-to-date growth rate higher than industry average at 69.51% against 17.40%. Revenue is forecast to grow 66.70% this quarter before jumping 81.80% for the next one. The rating firms project that company’s revenue will shrink -52.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 250k. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 240k.
ENSC Dividends
Ensysce Biosciences Inc has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Ensysce Biosciences Inc (NASDAQ:ENSC)’s Major holders
Ensysce Biosciences Inc insiders hold 1.17% of total outstanding shares, with institutional holders owning 3.35% of the shares at 3.39% float percentage. In total, 3.35% institutions holds shares in the company, led by PLANTE MORAN FINANCIAL ADVISORS, LLC. As of 2024-06-30, the company held over 20.0 shares (or 0.0004% of shares), all amounting to roughly $10.0.
